Establishing risk groups of multidrug-resistant  tuberculosis and planning its therapeutic approach by Boiko, Anna Vuktorivna et al.
 173 
Буковинський медичний вісник        Том 15, № 2 (58), 2011 
 
Abstract. Patients with a failure of the first and sec-
ond course of chemotherapy have a high risk of multidrug 
resistance tuberculosis amoung 227 persons under study 
(with the rate over 80 %); patients with a tuberculosis 
relapse – with the rate – 52,3 %, patients with interrupted 
treatment according to clinical category I – 43,3 %. 
Key words: multidrug resistance rate of tuberculous 
mycobacteria, new-onset pulmonary tuberculosis, tubercu-
losis relapses, chemoresistance. 
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Introduction. An important factor of the inci-
dence rate of tuberculosis (TB) in different countries 
of the world is a rapid spread of the strains of the 
mycobacteria of tuberculosis (MBT) resistant to anti-
tuberculous agents (ATA). Primary resistance de-
pends directly on the rate of acquired (secondary) 
resistance detected: the more patients excrete resis-
tant MBT strains the greater the likelihood for 
healthy persons to be infected with chemoresistant 
MBT strains [1, 2]. Polychemoresistance assumes 
important practical significance. According to WHO 
data about 50 million people in the world are in-
fected with MBT strains resistant to antimycobacte-
rial agents; annually the percentage of the emergence 
of new TB cases with primary medicamental resis-
tance is on the increase [3]. 
At the present time the basic treatment mode of 
this particular cohort of patients is prolonged and 
intensive chemotherapy to which MBT susceptibility 
is preserved. 
The outcome of such therapy depends on many 
factors – the nature and duration of the tuberculous 
process, the number of medications to which MBT is 
resistant, chemotherapeutic regimens – their inten-
sity, optimality, tolerance and duration, the availabil-
ity of necessary drugs, control and treatment and 
other factors.  
According to international and domestic recom-
mendations [4] pertaining to the treatment of patients 
with MRT of the lungs or a suspicion of it there exist 
several treatment regiments and a few approaches to 
a patient’s treatment, requiring the administration of 
a repeated course of chemotherapy [5, 7, 8, 10]. But 
neither of the approaches is universal, so long as it 
has both advantages and disadvantages [9]. To date 
the best policy as to the management of patients with 
a repeated treatment and a high risk of multidrug-
resistance has not been determined [6, 11]. 
First, for the reason that no groups of a high risk 
of multiresistance among persons with a repeated 
course of treatment have been established, secondly, 
owing to the fact that no controlled studies, dealing 
with an analysis of the efficacy of these approaches 
have been carried out, WHO is inclined to think that 
it is better to use standard regimens to treat patients 
with a repeated treatment, since owing to standardi-
zation they are less vulnerable as to the risk of fur-
ther spread of multidrug-resistance [7, 8, 12]. 
However, these inferences are purely theoretical 
and are not corroborated by controlled studies. More-
over, it is necessary to elaborate a standard regimen 
for each country and, probably, for a region of a 
country on the basis of the data of epidemmonitoring 
of medicamental resistance of MBT [8, 9]. 
A need of applying standard regimens of che-
motherapy in patients with a high risk of MRT is 
also stipulated by shortcomings of the drug MBT 
susceptibility testing. In order to evaluate the suscep-
tibility of MBT to antituberculous agents (ATA) at 
the Chernivtsi Regional TB Dispensary the method 
of inoculation on the Levenstein-Jensen medium 
based on the technique regulated by order №45 of 
Ukraine’s MHP of February 8, 2000 was used. The 
use of the routine methods of laboratory diagnostics 
of tuberculosis makes it possible to obtain the results 
of the test of MBT susceptibility to ATA in 3-3,5 
months since the first examination of a patient. 
Since Ukraine has no exact data, concerning the 
prevalence and profile of medicamental resistance of 
MBT a group of risk in relation to pulmonary mul-
tidrug-resistance tuberculosis of patients in whom 
unknown susceptibility of mycobacteria to ATA in 
Bucovyna must be determined on the basis of a co-
hort analysis of monitoring of the results of a previ-
ous course of treatment, the spread and the profile of 
resistance of mycobacteria of this particular cohort 
of patients. 
Taking into account the above-mentioned, the 
diagnosis of multiresistant tuberculosis is made, in 
the first place, on the basis of the results of treatment 
which are confirmed by the findings of drug suscep-
tibility and not on the contrary. 
The objective of research. To study risk groups, 
concerning the formation of multidrug-resistant pul-
monary tuberculosis and raise the efficacy of its treat-
ment in patients in whom susceptibility of the causa-
tive agent to antituberculous agents is unknown. 
Material and methods of the research. 227 
previously treated patients afflicted with new-onset 
tuberculosis and disease relapses have been exam-
ined, using a clinical, roentgenological, clinico-
laboratory, microbiological, statistical methods. 
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Results of the investigation and the subject 
under discussion. Among the persons under study 
(227 patients) there were 33 patients in whom a fail-
ure of the first course of chemotherapy (CT) was 
registered, 90 persons were with a suspended course 
of treatment for more than 2 months, 18 persons with 
a failed repeated course (there were both patients 
with NOTL and with recurrences) who were treated 
up to 10 months according to the second clinical 
category. 86 patients suffered from a TB relapse and 
who were not treated according to the second clinical 
category (Table 1). 
In conformity with the investigations carried out 
on the basis of the findings of statistical factors of 
active NOTL with bacterioexcretion of patients who 
were registered at the Chernivtsi Regional TB Dis-
pensary from 2002 to 2008 it has been established 
that the dynamics of general drug resistance among 
patients with tuberculosis detected for the first time 
did not change considerably, but multidrug resis-
tance is observed in 19% of retreated patients.  
Monitoring of multiresistance over the period 
from 2008 to 2010 has demonstrated that the dynam-
ics of MRT in newly detected patients has not relia-
bly changed. An essential increase of the number of 
patients with multidrug-resistant tuberculosis is ob-
served among retreated cohorts which exceeded 2.8 
times this index in 2010 as compared with 2008 that 
is indicative of insufficient efficacy of chemotherapy 
used in this particular cohort of patients. 
It has been established that among 227 exami-
nees the level of MBT multiresistance fluctuated 
from 43.3% in patients with suspended treatment to 
88,8 % in patients with a failure of a repeated course 
of chemotherapy. 
However, in order to define the degree of prob-
ability in each group of these patients we made use 
of the definition of the odds ratio concerning the 
presence of multidrug resistance in them. These find-
ings are presented in Table 2. 
A correlation between a patient’s medical his-
tory relative to the previous treatment and the pres-
ence of multidrug resistance was evaluated be means 
of the odds ratio (OR) according to a 4-column table 
compiled on the principle of comparing two groups 
with the presence and absence of a sign that is under 
study. If the value of the ratio of chances for un-
wanted sequelae is less than 1 this is an indication of 
a positive effect of the factor in question directed at 
reducing a risk of this sequela. 
With a low frequency of an event the value of 
the odds ratio equals approximately a relative risk. If 
the value of the odds ratio is more than 1, it was in-
dicative of a high risk of the influence of the factor 
in question on the sign that is investigated. 
Thus, with the rate of multidrug resistance in the 
group of 22 % previously treated patients that consti-
tuted 56,8 %, we found out that reliably vulnerable 
groups concerning multidrug resistance are patients 
with a failure of the 1st and repeated course of chemo-
therapy with equally high values of the odds ratio 5,5 
and 6,08 (p>0,05) respectively. In patients with a sus-
pended course of treatment and disease relapses there 
exist a relative risk of the presence of multidrug-
resistance with the odds ratio – 0,58 and 0,83 respec-
tively that does not differ considerably between them-
selves (p>0,05) however, it is reliably lower than in 
patients of the previous groups (p<0,05). 
The studies presented make it possible to single 
out groups of patients who should not be treated ac-
Table 2 
The ratio of chances as to the presence of multidrug resistance in patients with NOTL  
and disease recurrences, requiring the administration of retreatment 
Groups of patients treated earlier 
Multidrug resistance of MBT 
OR (95 % CI) There is There isn’t 
abs. % abs. % 
Failure of the 1st course of CT 29 87,9 4 12,1 5,5 (1,87-16,18) 
Suspended treatment 39 43,3 51 56,7 0,58 (0,35-0,95) 
Failure of the 2nd course of CT 16 88,8 2 11,2 6,08 (1,36-27,05) 
Recurrence 45 52,3 41 47,7 0,83 (0,5-1,37) 
Total 129 56,8 98 43,2   
The number of patients 
Total 
The type of a case of the tuberculosis disease 
Suspended treatment Failure of the 1
st course 
of treatment 
Failure of the 2nd 
course of treatment Tuberculosis relapse 
Abs. % Abs. % Abs. % Abs. % 
227 90 39,6 33 14,5 18 7,9 86 37,9 
Table 1 
The structure of the cohort of patients with pulmonary tuberculosis who require  
retreatment based on the type of a case of the tuberculosis disease 
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cording to category 2 with the use of the first-line 
medications due to a high likelihood of the presence 
of MBT multidrug resistance: the patients with a de-
fault of the first and a repeated course of chemother-
apy (the odds ratio (OR) – 5,5 and 6,08. The patients 
with a suspended treatment and disease relapses have 
a relative risk of available MBT multidrug resistance 
(the odds ratio (OR) – 0,58 and 0,83). 
Patients with a failure of the first and repeated CT 
course should be prescribed standard regimens of CT 
based on the 4th category in case of the absence of the 
test of drug susceptibility of MBT to first-line ATAs. 
In patients with suspended therapy and tubercu-
losis recurrences preference should be given to em-
piric CT regimens over standard regimens based on 
the second clinical category so long as they include 
5-7 medications with a view of preserving rather a 
high likelihood that tuberculosis mycobacteria will 
retain susceptibility at least to 4 of them. 
In accordance with the findings of the research, 
the regimen based on the second clinical category 
fits to only half of the patients (47,7 %), first-line 
antituberculous agents being used in it. 
We have carried out an analysis of the findings, 
dealing with MBT susceptibility to ATAs in 43 patients 
with NOTL with a suspicion of multidrug resistant tu-
berculosis and unknown susceptibility of the causative 
agent to antituberculous drugs (the presence of the mul-
tidrug resistance was established upon obtaining the 
results of MBT drug susceptibility testing). 
Extensive resistance of MBT was identified in 
almost half of the patients (44,2 %) with MRT, ex-
cept the basic antituberculosis drugs (isoniazid and 
rifampicin): to streptomycin – in 55,5 % of the pa-
tients, pyrazinamide – in 27,9 %, ethambutol – in 
32,6 %. In other words, the administration of a re-
peated course to half of the patients based on the 2nd 
clinical category is impossible. 
A relatively not high level of MBT resistance to 
kanamycin (K) and ethionamid (Et) – 2,3 % and 
1,6 % respectively was observed among the persons 
under study, enabling to use these drugs in patients 
requiring retreatment under the standard regimens of 
chemotherapy according to the 4th clinical category. 
We have carried out a comparative analysis of 
the efficiency of various regimens of chemotherapy 
in patients with pulmonary tuberculosis with un-
known susceptibility of tuberculosis mycobacteria to 
antimycobacterial drugs among groups of risk of the 
development of multidrug resistant tuberculosis.  
By the time of obtaining the test of MBT sus-
ceptibility to ATAs the findings had been analyzed: 
sputum conversion in 76,9 % of the cases occurred at 
the expense of administering the empiric regimen of 
chemotherapy to the patients, the treatment based on 
the 1st category – in 52 % of the patients, according 
to the 2nd category – 40 % of the cases. The cessation 
of bacterioexcretion based on a swab in 29 cases 
(67,4 %) based on a culture – 14 (32,6 %), a decrease 
of bacterioexcretion in 39,5 % (17 persons) of the 
cases. Partial resorption of focal-infiltrative changes 
was observed in 48,8 %, insignificant regression of 
caverns was marked in 39.5 % (17 patients). An 
abatement of clinical manifestations was established 
in 39,5 % of the cases (17 persons). 
The efficiency of the standard and individual 
regimens of chemotherapy was evaluated in 6 
months since the initiation of the treatment. A de-
crease of bacterioexcretion at this moment with the 
standard and individual regimens of chemotherapy 
occurred for certain in 15 % and 60,9 % respectively. 
Partial resorption of focal-infiltrative changes in 
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Fig. 2. Efficiency of the chemotherapeutic regimen upon discharging 
Fig 1. Efficiency of chemotherapy regimens 
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70 % and 60,9 %, a regression of caverns under the 
existing regimens distinguished considerably, 65 % 
versus 21,7 % regression of caverns. Positive 
changes in a common blood analysis were observed 
in case of the standard regimen – 85 % and 34,8 % in 
case of the individual one, improved clinical mani-
festations – 80 % and 43,8 % respectively and these 
are illustrated in Fig. 1. 
Thus, in spite of an individual selection of che-
motherapy, preference was given to the standard 
regimen of chemotherapy (p>0,05). 
The next evaluation of regimens was carried out 
on discharging the patients from the in-patient de-
partment, in 16,8±7,2 months on the average. A 
complete stoppage of bacteriosecretion is observed 
in 90 % in case of the standard regimen, whereas 
with the individual one – in 56,5 % of the cases. 
Complete resorption of focal- infiltrative changes 
was observed in 50 % of the patients and 26,1 % 
respectively. Cavernous regression with the standard 
regimen is seen in 55 % of the patients, whereas in 
case of the individual regimen – in 21,7 % of the 
cases. A normalization of the indices of the general 
blood analysis in case of the standard and individual 
regimens of chemotherapy was marked in 90 % and 
65,2 % of the persons respectively. The absence of 
the basic clinical manifestations under these condi-
tions was observed in 90 % in case of the standard 
regimen and 39,1 % with the individual one and is 
demonstrated in Fig. 2. 
Thus, the most effective regimen of chemother-
apy in patients with multi-drug resistant tuberculosis 
was the standard one.  
Having analyzed the results of the treatment, it 
turned out that in connection with stabilization of the 
pulmonary process and a cessation of bacterioexcre-
tion in patients with multi-drug resistant pulmonary 
tuberculosis as much as 72,1 % (31) of the patients 
were discharged from hospital. 19,4 % (6) out of them 
were readmitted in a certain period of time, taking 
into account periodic exacerbations of this particular 
disease. Two persons (4,7 %) were discharged with a 
postmortem epicrisis, due to a break of the hospital 
regimen, 23,2 % (10) of the patients were transferred 
to a course of aftercare under the in patients condi-
tions of the Molodiia Interdistrict TB Dispensary.  
Thus, summarizing the above stated, one can 
say, that recovery was observed in 55 % (11) of the 
cases, a stoppage of bacterioexcretion – in 35 % (7) 
among patients with multidrug-resistant tuberculosis 
of the lungs who were administered the standard regi-
men of chemotherapy. Recovery among persons ad-
ministered the individual regimen of chemotherapy 
was registered in 21,7 % (5) of the persons, a stop-
page of bacterioexcretion – in 34,8 % (8 patients).  
The findings obtained as a result of the research 
carried out by the authors agree with those of other 
studies that point out the efficiency of the empiric 
regimen of chemotherapy towards the resistance of 
tuberculous mycobacteria at the expense of prescrib-
ing 5-7 drugs for the purpose of preserving rather a 
high likelihood of the fact that tuberculosis myco-
bacteria will retain susceptibility at least to 4 of 
them. Evaluating the regimens of chemotherapy on 
discharging from hospital, regardless of an individ-
ual selection of chemopreparations, the standard 
regimen turned out to be more effective (EK (Am) 
ZEt ( Pass) Q or EZEtPASSQ) on the basis of using 
2nd line medications and fluoroquinolones.  
For the sake of treating patients with multidrug-
resistant tuberculosis the following second-line drugs 
are used in Ukraine: ethionamide (prothionamide), 
kanamycin (amikacin), fluoroquinolones of different 
generations, PAS(A). Only streptomycin, ethambutol 
and pyrazinamide out of the first-line antituberculo-
sis drugs are good to be used in case of the develop-
ment of multidrug resistance. However, with exten-
sive medicamental resistance, as it was established 
by the results of our research, all the 1st-line antitu-
berculous drugs lose their potency. In other words, 
all in all, 4-7 antituberculosis drugs from all groups 
are available for the treatment of patients with mul-
tidrug-resistant tuberculosis.  
One of the basic principles of chemotherapy of 
patients with multidrug- resistant tuberculosis is the 
use of no less than 4 antimycobacterial drugs (first, 
second- line and reserve ones) to which MBT are 
susceptible in case of their satisfactory tolerance. But 
under the conditions of MBT resistance up to 4 and a 
larger number of antituberculous drugs and in many 
cases, in addition, intolerance of some of them it is 
impossible to provide a comprehensive regimen of 
antituberculosis therapy or institute therapy at all. 
The presence of extensive tolerance of MBT in 
a large enough number of patients with MRTB ex-
amined by us should be taken into account later on, 
when structuring empiric regimens of chemotherapy 
which are worth using in patients with suspended 
treatment and tuberculosis recurrences for the pur-
pose of avoiding the phenomenon of induction 
(enhancement) of MBT resistance to a greater num-
ber of ATAs. To use instead of pyrasinamide – 
ethionamide/prothionamide or cycloserine, instead of 
ethambutol – PAS(A), instead of streptomycin – 
kanamycin/amikacin. 
To-date, in the presence of extensive drug resis-
tance in patients with MRTB raising the efficacy of 
treatment of such patients is possible by many differ-
ent ways. The first one is synthesis of new antituber-
culous agents. But this way requires investing a lot 
of money and what is most important it is very pro-
longed. The second one is an evaluation of the anti-
tuberculosis activity of the antimycobacterial drugs 
of a wide spectrum of action. It is a promising trend 
which is being actively elaborated currently [7]. The 
antituberculous proprieties of fluoroquinolones, mac-
rolides and some other compounds have already 
been established. The third one is the most topical in 
Ukraine for to-day – the registration of the second-
line antituberculous agents already known and which 
are not produced in our country.  
Conclusions 
1. A very high risk of multidrug-resistant tuber-
culosis of the lungs is characteristic of patients with 
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failure of the first course of chemotherapy (87,9 %) 
and failure of the repeated course (88,8 %); a high 
risk of multidrug-resistant tuberculosis is inherent to 
patients with tuberculosis recurrence and suspended 
treatment in compliance with the 1st category (with 
the rate of 52,3 % and 43,3 % respectively). 
2. It is advisable to prescribe standard regimens 
of chemotherapy based on the 4th category to patients 
with a failure of the first and repeated course of che-
motherapy in case of the absence of the test of medi-
cal susceptibility of mycobacteria to antituberculous 
drugs of the first line.  
3. A relatively not high level of resistance of MBT 
to kanamycin (K) and ethionamide (ET) – respectively 
2,3 % and 1,6 % among the persons under study en-
ables to use these drugs in patients, requiring retreat-
ment in terms of standard regimens of chemotherapy in 
accordance with the 4th clinical category prior to obtain-
ing the results of MBT drug susceptibility testing. 
4. Taking into consideration the presence of 
extensive medicamental resistance in 44,2 % of the 
patients with multidrug-resistant tuberculosis in case 
of administering empiric regimens to patients with a 
tuberculosis relapse or suspended treatment prefer-
ence should be given to oral antituberculosis drugs of 
the second-line (ehionamide, prothionamide, cyclos-
erine, PAS(A)) with a view of avoiding the phe-
nomenon of MBT resistance induction to a greater 
number of ATAs. 
5. While comparing the efficacy of different 
regimens of chemotherapy in patients afflicted with 
pulmonary tuberculosis, it has been established that 
the most effective regimen is the empiric regimen of 
chemotherapy (EZS(К)PASQ or EZK(Pt/Сap)CsQ) 
prior to evaluating tuberculous mycobacteria resis-
tance (the basic course), at the expense of prescribing 
a combination of 5-7 drugs During a stage of continu-
ing treatment, evaluating the regimens of chemother-
apy upon discharging from hospital, the standard regi-
men turned out to be more effective (EK(Am)ZEt
(PASS)Q or EZEtPASSQ at the expense of using 
second-line drugs and fluoroquinolones. 
Practical value of the results obtained. Risk 
groups in which, multidrug-resistant pulmonary tuber-
culosis may develop have been established. The au-
thors have carried out an analysis of the efficacy of the 
most rational regiments of chemotherapy of patients 
with pulmonary tuberculosis with due regard for an 
evaluation of antimycobacterial susceptibility of the 
causative agent enabling to improve the results of che-
motherapy of this particular category of patients and 
forestalling the development of multiresistant forms. 
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УСТАНОВЛЕНИЕ ГРУПП РИСКА МУЛЬТИРЕЗИСТЕНТНОГО  
ТУБЕРКУЛЕЗА И ОПРЕДЕЛЕНИЕ ТАКТИКИ ЛЕЧЕНИЯ 
А.В.Бойко, Л.Д.Тодорико, Л.Д.Mыгайлюк, И.В.Еременчук, А.M.Барбэ 
Резюме. Среди 227 исследуемых лиц высокий риск мультирезистентного туберкулеза (с частотой свыше 
80 %) имеют пациенты с неудачей первого и второго курсов химиотерапии; с частотой 52,3 % – пациенты с реци-
дивом туберкулеза, с частотой 43,3 % – пациенты с прерванным лечением за 1 клинической категорией. 
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Резюме. Серед 227 досліджуваних осіб високий ризик мультирезистентного туберкульозу (з частотою понад 
80 %) мають пацієнти з невдачею першого та другого курсу хіміотерапії; з частотою 52,3 % – пацієнти з рецидивом 
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